The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization
Abstract
Background: Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome and display higher on-clopidogrel platelet reactivity compared with younger patients. Prasugrel 5 mg provides more predictable platelet inhibition compared with clopidogrel in the elderly, suggesting the possibility of reducing ischemic events without increasing bleeding. Methods: In a multicenter, randomized, open-label, blinded end point trial, we compared a once-daily maintenance dose of prasugrel 5 mg with the standard clopidogrel 75 mg in patients >74 years of age with acute coronary syndrome undergoing percutaneous coronary intervention. The primary end point was the composite of mortality, myocardial infarction, disabling stroke, and rehospitalization for cardiovascular causes or bleeding within 1 year. The study was designed to demonstrate superiority of prasugrel 5 mg over clopidogrel 75 mg. Results: Enrollment was interrupted, according to prespecified criteria, after a planned interim analysis, when 1443 patients (40% women; mean age, 80 years) had been enrolled with a median follow-up of 12 months, because of futility for efficacy. The primary end point occurred in 121 patients (17%) with prasugrel and 121 (16.6%) with clopidogrel (hazard ratio, 1.007; 95% confidence interval, 0.78–1.30; P =0.955). Definite/probable stent thrombosis rates were 0.7% with prasugrel versus 1.9% with clopidogrel (odds ratio, 0.36; 95% confidence interval, 0.13–1.00; P =0.06). Bleeding Academic Research Consortium types 2 and greater rates were 4.1% with prasugrel versus 2.7% with clopidogrel (odds ratio, 1.52; 95% confidence interval, 0.85–3.16; P =0.18). Conclusions: The present study in elderly patients with acute coronary syndromes showed no difference in the primary end point between reduced-dose prasugrel and standard-dose clopidogrel. However, the study should be interpreted in light of the premature termination of the trial. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01777503.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Cayla, G., Cuisset, T., Silvain, J., Leclercq, F., Manzo-Silberman, S., Saint-Etienne, C., Delarche, N., Bellemain-Appaix, A., Range, G., El Mahmoud, R., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31323-x · Cited by 380
Cited by
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Damluji, A. A., Forman, D. E., Wang, T. Y., Chikwe, J., Kunadian, V., Rich, M. W., Young, B. A., Page, R. L., DeVon, H. A., Alexander, K. P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001112 · Cited by 348
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Metadata
- Authors
- Savonitto, S., Ferri, L. A., Piatti, L., Grosseto, D., Piovaccari, G., Morici, N., Bossi, I., Sganzerla, P., Tortorella, G., Cacucci, M., Ferrario, M., Murena, E., Sibilio, G., Tondi, S., Toso, A., Bongioanni, S., Ravera, A., Corrada, E., Mariani, M., Di Ascenzo, L., Petronio, A. S., Cavallini, C., Vitrella, G., Rogacka, R., Antonicelli, R., Cesana, B. M., De Luca, L., Ottani, F., De Luca, G., Piscione, F., Moffa, N., De Servi, S., Bolognese, L., Bovenzi, F., Steffenino, G., Santilli, I., Bassanelli, G., Sacco, A., Canziani, F., Ferri, M., Lo Jacono, E., Canosi, U., Fornaro, G., Leoncini, M., Rosa Conte, M., Farina, R., Stefanin, C., Di Pede, F., Chella, P., Chiara Nardoni, M., Tamburrini, P., Trimarco, B., Galasso, G., Elia, R., Bolognese, L., Grotti, S., Bovenzi, F., Borrelli, L., Tamburino, C., Capranzano, P., Francaviglia, B., Campana, C., Bonatti, R., Martinoni, A., Abate, F., Coscarelli, S., Rubartelli, P., Villani, G. Q., & Rossini, R.
- Venue
- Circulation
- Published
- 2018-06-05
- Volume
- 137
- Issue
- 23
- Pages
- 2435-2445
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2788079067
- Cited by
- 159
- References
- 5
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.